奥扎格雷（阿普司特 30 毫克片剂）。

Otezla (Apremilast 30-Mg Tablets).

机构信息

Department of Medicine, Baylor Scott & White University Hospital, Dallas, TX.

Dermatology Treatment and Research Center, Dallas, TX;

出版信息

Skinmed. 2024 Aug 2;22(3):218-219. eCollection 2024.

Abstract

Otezla was first approved on March 21, 2014 for the treatment of psoriatic arthritis, on September 23, 2014 for moderate to severe plaque psoriasis and on July 19, 2019 for the treatment of oral ulcers associated with Behcet's disease (BD). Apremilast is an inhibitor of phosphodi-esterase-4, an enzyme involved in the pathogenesis of several dermatologic conditions. This review explores the potential utility of apremilast in the treatment of other unapproved dermatologic indications.

摘要

奥扎替尼于 2014 年 3 月 21 日首次获批用于治疗银屑病关节炎，2014 年 9 月 23 日用于治疗中重度斑块型银屑病，2019 年 7 月 19 日用于治疗白塞病（BD）相关口腔溃疡。阿普米司特是磷酸二酯酶-4 的抑制剂，该酶参与多种皮肤病的发病机制。本综述探讨了阿普米司特在治疗其他未经批准的皮肤科适应证方面的潜在用途。